Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 797898, 8 pages
http://dx.doi.org/10.1155/2014/797898
Review Article

Therapeutic Potential of MicroRNA: A New Target to Treat Intrahepatic Portal Hypertension?

1Division of Gastroenterology and Hepatology, School of Medicine, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University, 145 Shandong Middle Road, Shanghai, 200001, China
2Digestive Disease Laboratory, Department of Gastroenterology, School of Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai 200092, China

Received 18 November 2013; Revised 9 February 2014; Accepted 18 March 2014; Published 9 April 2014

Academic Editor: Wei Mike Liu

Copyright © 2014 Can-Jie Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Leuci, G. Pomarico, N. Casucci, B. Fucci, N. D'Alitto, and A. Caldarone, “Primary prophylaxis of esophageal variceal bleeding in cirrhotic patients,” Recenti Progressi in Medicina, vol. 99, no. 12, pp. 607–610, 2008. View at Google Scholar · View at Scopus
  2. L. R. Jiao, F. S. Inglott, R. T. Mathie, and N. A. Habib, “The effect of augmenting portal venous inflow on intrahepatic pressure and resistance in the isolated perfused porcine liver,” Hepato-Gastroenterology, vol. 48, no. 40, pp. 1011–1014, 2001. View at Google Scholar · View at Scopus
  3. H. Reynaert, M. G. Thompson, T. Thomas, and A. Geerts, “Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension,” Gut, vol. 50, no. 4, pp. 571–581, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Kitao, Y. Sato, S. Sawada-Kitamura et al., “Endothelial to mesenchymal transition via transforming growth factor-β1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension,” The American Journal of Pathology, vol. 175, no. 2, pp. 616–626, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Fernandez, M. Mejias, E. Garcia-Pras, R. Mendez, J. C. Garcia-Pagan, and J. Bosch, “Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats,” Hepatology, vol. 46, no. 4, pp. 1208–1217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Shah, P. Leidinger, N. Blin, and E. Meese, “miRNA: small molecules as potential novel biomarkers in cancer,” Current Medicinal Chemistry, vol. 17, no. 36, pp. 4427–4432, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Xiong, W. Jiang, R. Zhou, C. Mao, and Z. Guo, “Identification and analysis of the regulatory network of Myc and microRNAs from high-throughput experimental data,” Computers in Biology and Medicine, vol. 43, no. 9, pp. 1252–1260, 2013. View at Publisher · View at Google Scholar
  8. V. Ambros, “The functions of animal microRNAs,” Nature, vol. 431, no. 7006, pp. 350–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Liu, S. H. Chen, X. Jin, and Y. M. Li, “Analysis of differentially expressed genes and microRNAs in alcoholic liver disease,” International Journal of Molecular Medicine, vol. 31, no. 3, pp. 547–554, 2013. View at Google Scholar
  10. V. Hernandez-Gea, F. Turon, A. Berzigotti, and A. Villanueva, “Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension,” World Journal of Gastroenterology, vol. 19, no. 8, pp. 1193–1199, 2013. View at Publisher · View at Google Scholar
  11. D. Thabut and V. Shah, “Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?” Journal of Hepatology, vol. 53, no. 5, pp. 976–980, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. S. Thimgan and H. F. Yee Jr., “Quantitation of rat hepatic stellate cell contraction: stellate cells' contribution to sinusoidal resistance,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 277, part 1, pp. G137–G143, 1999. View at Google Scholar · View at Scopus
  13. S. L. Friedman, “Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 1, no. 2, pp. 98–105, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Fallowfield A Hayden, V. Snowdon et al., “Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo,” Hepatology, vol. 59, no. 4, pp. 1492–1504, 2013. View at Publisher · View at Google Scholar
  15. M. Pinzani and F. Marra, “Cytokine receptors and signaling in hepatic stellate cells,” Seminars in Liver Disease, vol. 21, no. 3, pp. 397–416, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. T. K. Gupta, L. Chen, and R. J. Groszmann, “Pathophysiology of portal hypertension,” Baillière's Clinical Gastroenterology, vol. 11, no. 2, pp. 203–219, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Reynaert, D. Urbain, and A. Geerts, “Regulation of sinusoidal perfusion in portal hypertension,” Anatomical Record, vol. 291, no. 6, pp. 693–698, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. J. S. Lee and J. H. Kim, “The role of activated hepatic stellate cells in liver fibrosis, portal hypertension and cancer angiogenesis,” The Korean Journal of Hepatology, vol. 13, no. 3, pp. 309–319, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Fernandez, M. Mejias, E. Garcia-Pras, R. Mendez, J. C. Garcia-Pagan, and J. Bosch, “Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats,” Hepatology, vol. 46, no. 4, pp. 1208–1217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Y. Kim and S. K. Baik, “Pathophysiology of portal hypertension, what's new?” The Korean Journal of Gastroenterology, vol. 56, no. 3, pp. 129–134, 2010. View at Google Scholar · View at Scopus
  21. F. Jiang, C. J. Parsons, and B. Stefanovic, “Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation,” Journal of Hepatology, vol. 45, no. 3, pp. 401–409, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Maubach, M. C. Lim, J. Chen, H. Yang, and L. Zhuo, “miRNA studies in in vitro and in vivo activated hepatic stellate cells,” World Journal of Gastroenterology, vol. 17, no. 22, pp. 2748–2773, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Zheng, Z. Lin, P. Dong et al., “Activation of hepatic stellate cells is suppressed by microRNA-150,” International Journal of Molecular Medicine, vol. 32, no. 1, pp. 17–24, 2013. View at Publisher · View at Google Scholar
  24. T. Ogawa, M. Enomoto, H. Fujii et al., “MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis,” Gut, vol. 61, no. 11, pp. 1600–1609, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Chen, C.-Q. Wu, Z.-Q. Zhang, D.-K. Yao, and L. Zhu, “Loss of expression of miR-335 is implicated in hepatic stellate cell migration and activation,” Experimental Cell Research, vol. 317, no. 12, pp. 1714–1725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. C.-J. Guo, Q. Pan, D.-G. Li, H. Sun, and B.-W. Liu, “miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis,” Journal of Hepatology, vol. 50, no. 4, pp. 766–778, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. He, C. Huang, S. P. Zhang, X. Sun, X.-R. Long, and J. Li, “The potential of microRNAs in liver fibrosis,” Cellular Signalling, vol. 24, no. 12, pp. 2268–2272, 2012. View at Publisher · View at Google Scholar
  28. S. Vettori, S. Gay, and O. Distler, “Role of microRNAs in fibrosis,” The Open Rheumatology Journal, vol. 6, pp. 130–139, 2012. View at Publisher · View at Google Scholar
  29. C.-J. Guo, Q. Pan, B. Jiang, G.-Y. Chen, and D.-G. Li, “Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells,” Apoptosis, vol. 14, no. 11, pp. 1331–1340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Ji, J. Zhang, G. Huang, J. Qian, X. Wang, and S. Mei, “Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation,” FEBS Letters, vol. 583, no. 4, pp. 759–766, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Wei, L. Feng, Z. Li, G. Xu, and X. Fan, “MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling,” Biomedicine & Pharmacotherapy, vol. 67, no. 5, pp. 387–392, 2013. View at Publisher · View at Google Scholar
  32. Z. Meng, X. Fu, X. Chen et al., “miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice,” Hepatology, vol. 52, no. 6, pp. 2148–2157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. He, C. Huang, X. Sun, X.-R. Long, X.-W. Lv, and J. Li, “MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4,” Cellular Signalling, vol. 24, no. 10, pp. 1923–1930, 2012. View at Publisher · View at Google Scholar
  34. Y. Sekiya, T. Ogawa, K. Yoshizato, K. Ikeda, and N. Kawada, “Suppression of hepatic stellate cell activation by microRNA-29b,” Biochemical and Biophysical Research Communications, vol. 412, no. 1, pp. 74–79, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Sekiya, T. Ogawa, M. Iizuka, K. Yoshizato, K. Ikeda, and N. Kawada, “Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-β-induced inhibition of hepatic stellate cell proliferation,” Journal of Cellular Physiology, vol. 226, no. 10, pp. 2535–2542, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Wang, W. Li, K. Guo, Y. Xiao, Y. Wang, and J. Fan, “miR-181b Promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients,” Biochemical and Biophysical Research Communications, vol. 421, no. 1, pp. 4–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. N. M. Steuerwald, T. L. Walling, S. Ghosh et al., “Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis,” Hepatology, vol. 56, no. 1, pp. 300–310, 2012. View at Publisher · View at Google Scholar
  38. K. J. Thompson, I. H. Mckillop, and L. W. Schrum, “Targeting collagen expression in alcoholic liver disease,” World Journal of Gastroenterology, vol. 17, no. 20, pp. 2473–2481, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. R. S. McCuskey, “The hepatic microvascular system in health and its response to toxicants,” Anatomical Record, vol. 291, no. 6, pp. 661–671, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Ogawa, M. Iizuka, Y. Sekiya, K. Yoshizato, K. Ikeda, and N. Kawada, “Suppression of type I collagen production by microRNA-29b in cultured human stellate cells,” Biochemical and Biophysical Research Communications, vol. 391, no. 1, pp. 316–321, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. Y.-Y. Yang, T.-H. Tsai, Y.-T. Huang et al., “Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats,” Hepatology, vol. 55, no. 5, pp. 1540–1550, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. J. E. Fish, M. M. Santoro, S. U. Morton et al., “miR-126 regulates angiogenic signaling and vascular integrity,” Developmental Cell, vol. 15, no. 2, pp. 272–284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Zhu and G. C. Fan, “Role of microRNAs in the reperfused myocardium towards post-infarct remodelling,” Cardiovascular Research, vol. 94, no. 2, pp. 284–292, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Noetel, N. Elfimova, J. Altmüller et al., “Next generation sequencing of the Ago2 interacting transcriptome identified chemokine family members as novel targets of neuronal microRNAs in hepatic stellate cells,” Journal of Hepatology, vol. 58, no. 2, pp. 335–341, 2013. View at Publisher · View at Google Scholar
  45. F. Yu, Z. Lin, J. Zheng, S. Gao, Z. Lu, and P. Dong, “Suppression of collagen synthesis by Dicer gene silencing in hepatic stellate cells,” Molecular Medicine Reports, vol. 9, no. 2, pp. 707–714, 2014. View at Publisher · View at Google Scholar
  46. Y. Liu, X. M. Wen, E. L. H. Lui et al., “Therapeutic targeting of the PDGF and TGF-Β-signaling pathways in hepatic stellate cells by PTK787/ZK22258,” Laboratory Investigation, vol. 89, no. 10, pp. 1152–1160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Sauvant, M. Cansell, and C. Atgie, “Vitamin A and lipid metabolism: relationship between hepatic stellate cells (HSCs) and adipocytes,” Journal of Physiology and Biochemistry, vol. 67, no. 3, pp. 487–496, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Kong, F. Zhang, D. Wei et al., “Paeonol inhibits hepatic fibrogenesis via disrupting nuclear factor-κB pathway in activated stellate cells: in vivo and in vitro studies,” Journal of Gastroenterology and Hepatology, vol. 28, no. 7, pp. 1223–1233, 2013. View at Publisher · View at Google Scholar
  49. N.-L. Zhu, K. Asahina, J. Wang et al., “Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration,” The Journal of Biological Chemistry, vol. 287, no. 13, pp. 10355–10367, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Zhao, Y. Wang, Q. Wang, Z. Liu, Q. Liu, and X. Deng, “Hepatic stellate cells produce vascular endothelial growth factor via phospho-p44/42 mitogen–activated protein kinase/cyclooxygenase-2 pathway,” Molecular and Cellular Biochemistry, vol. 359, no. 1-2, pp. 217–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. C.-J. Guo, Q. Pan, T. Cheng, B. Jiang, G.-Y. Chen, and D.-G. Li, “Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways,” FEBS Journal, vol. 276, no. 18, pp. 5163–5176, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Cao, U. Yaqoob, A. Das et al., “Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-β signaling in hepatic stellate cells,” The Journal of Clinical Investigation, vol. 120, no. 7, pp. 2379–2394, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Majumder, A. C. Piguet, J. F. Dufour, and S. Chatterjee, “Study of the cellular mechanism of sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis,” European Journal of Pharmacology, vol. 705, no. 1–3, pp. 86–95, 2013. View at Publisher · View at Google Scholar
  54. K. Breitkopf, P. Godoy, L. Ciuclan, M. V. Singer, and S. Dooley, “TGF-β/Smad signaling in the injured liver,” Zeitschrift für Gastroenterologie, vol. 44, no. 1, pp. 57–66, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Liang, X. Deng, Z.-X. Lin, L.-C. Zhao, and X.-L. Zhang, “Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis,” World Journal of Gastroenterology, vol. 15, no. 36, pp. 4529–4537, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. A. M. Lakner, N. M. Steuerwald, T. L. Walling et al., “Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis,” Hepatology, vol. 56, no. 1, pp. 300–310, 2012. View at Google Scholar
  57. Y. He, C. Huang, X. Sun, X.-W. Lv, and J. Li, “MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4,” Cellular Signalling, vol. 24, no. 10, pp. 1923–1930, 2012. View at Publisher · View at Google Scholar
  58. A. Noetel, M. Kwiecinski, N. Elfimova, J. Huang, and M. Odenthal, “MicroRNA are central players in anti- and profibrotic gene regulation during liver fibrosis,” Frontiers in Physiology, vol. 19, no. 3, article 49, 2012. View at Publisher · View at Google Scholar
  59. O. Rosmorduc and C. Housset, “Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease,” Seminars in Liver Disease, vol. 30, no. 3, pp. 258–270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Corpechot, V. Barbu, D. Wendum et al., “Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis,” Hepatology, vol. 35, no. 5, pp. 1010–1021, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Zhao, Y. Wang, Q. Wang, Z. Liu, Q. Liu, and X. Deng, “Hepatic stellate cells produce vascular endothelial growth factor via phospho-p44/42 mitogen-activated protein kinase/cyclooxygenase-2 pathway,” Molecular and Cellular Biochemistry, vol. 359, no. 1-2, pp. 217–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Valfre di Bonzo, E. Novo, S. Cannito et al., “Angiogenesis and liver fibrogenesis,” Histology and Histopathology, vol. 24, no. 10, pp. 1323–1341, 2009. View at Google Scholar · View at Scopus
  63. K. Taura, S. Minicis, E. Seki et al., “Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis,” Gastroenterology, vol. 135, no. 5, pp. 1729–1738, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Fernandez, M. Mejias, B. Angermayr, J. C. Garcia-Pagan, J. Rodes, and J. Bosch, “Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats,” Journal of Hepatology, vol. 43, no. 1, pp. 98–103, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Urbich, A. Kuehbacher, and S. Dimmeler, “Role of microRNAs in vascular diseases, inflammation, and angiogenesis,” Cardiovascular Research, vol. 79, no. 4, pp. 581–588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Zhou, M. McMaster, K. Woo et al., “Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome,” The American Journal of Pathology, vol. 160, no. 4, pp. 1405–1423, 2002. View at Google Scholar · View at Scopus
  67. R. C. Huebert, K. Jagavelu, H. I. Hendrickson et al., “Aquaporin-1 promotes angiogenesis, fibrosis, and portal hypertension through mechanisms dependent on osmotically sensitive microRNAs,” The American Journal of Pathology, vol. 179, no. 4, pp. 1851–1860, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. C. J. Guo, Q. Pan, H. Xiong et al., “Dynamic expression of miR-126 and its effects on proliferation and contraction of hepatic stellate cells,” FEBS Letters, vol. 587, no. 23, pp. 3792–3801, 2013. View at Publisher · View at Google Scholar
  69. D. Thabut, C. Routray, G. Lomberk et al., “Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis,” Hepatology, vol. 54, no. 2, pp. 573–585, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Takahashi, N. Yamada, H. Hatakeyama et al., “In vitro optimization of 2′-OMe-4′-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle,” Nucleic Acids Research, vol. 41, no. 22, pp. 10659–10667, 2013. View at Publisher · View at Google Scholar
  71. H. Baigude and T. M. Rana, “Interfering nanoparticles for silencing microRNAs,” Methods in Enzymology, vol. 509, pp. 339–353, 2012. View at Google Scholar
  72. X. Wang, B. Yu, W. Ren et al., “Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations,” Journal of Controlled Release, vol. 172, no. 3, pp. 690–698, 2013. View at Publisher · View at Google Scholar
  73. L. Wang, W. Tang, S. Yan et al., “Efficient delivery of miR-122 to regulate cholesterol metabolism using a non-covalent peptide-based strategy,” Molecular Medicine Reports, vol. 8, no. 5, pp. 1472–1478, 2013. View at Publisher · View at Google Scholar
  74. Y. Zhang, K. J. Fan, Q. Sun et al., “Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-β signalling pathway,” Nucleic Acids Research, vol. 40, no. 18, pp. 9286–9297, 2012. View at Publisher · View at Google Scholar
  75. Y. Zhang, Z. Wang, and R. A. Gemeinhart, “Progress in microRNA delivery,” Journal of Controlled Release, vol. 172, no. 3, pp. 962–974, 2013. View at Publisher · View at Google Scholar
  76. H. Hidaka, T. Nakazawa, A. Shibuya et al., “Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial,” Journal of Gastroenterology, vol. 46, no. 11, pp. 1316–1323, 2011. View at Publisher · View at Google Scholar · View at Scopus